Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209296 | 0.85 | CYP2A6 (0.38) | NR4A2CYP2A6NOS1DYRK1APDGFRB | |
| SCHEMBL209074 | 0.75 | BACE1 (0.38) | CYP2A6AHRBACE1 | |
| SCHEMBL2358946 | 0.75 | CYP1A2 (0.42) | CYP2A6NOS1BACE1 | |
| SCHEMBL208082 | 0.75 | BACE1 (0.38) | CYP2A6NOS1DYRK1AAHRBACE1 | |
| SCHEMBL1450911 | 0.75 | MEN1 (0.38) | PDGFRBPDGFRA | |
| SCHEMBL15670712 | 0.71 | BACE1 (0.43) | DYRK1ABACE1 | |
| SCHEMBL15512385 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL208799 | 0.71 | HDAC8 (0.34) | — | |
| SCHEMBL577221 | 0.71 | ALDH1A1 (0.36) | TP53 | |
| SCHEMBL577957 | 0.69 | BACE1 (0.38) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408392-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140378461-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| EP-2814321-A2 | NEMATICIDAL CIS (HETERO)ARYLCYCLOPROPYLCARBOXAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120940-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101163700-A | Triamine derivative | DAIICHI SEIYAKU CO (JP) | 2008-04-16 | — | — | CN | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| CN-1420882-A | Substd. oxoazaheterocyclyl compounds | AVENTIS PHARM PROD INC (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | NR4A2 2622/4885CYP2A6 246/4885NOS1 728/4885 |
| US-20140378461-A1 | NOVEL COMPOUNDS | CYP1B1, DDT, CYP51A1 | NR4A2 2070/4885CYP2A6 306/4885NOS1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.